adlbh/factuality-prediction-dataset · Datasets at Hugging Face

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1208-1254

1244-1254

T66

angiotensin-converting enzyme inhibitors

PharmacologicSubstance

1,208

1,254

preserve

1364-1372

T70

patients

PatientOrDisabledGroup

1,364

1,372

A1

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), @SUBJECT$ , beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1329-1338

1337-1338

T69

vitamin E

Lipid

1,329

1,338

preserve

1364-1372

T70

patients

PatientOrDisabledGroup

1,364

1,372

A2

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and @SUBJECT$ should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.

Fact

preserve

1528-1530

T91

to

higher_than

1,528

1,530

preserve

1478-1515

1507-1515

T84

coronary artery bypass grafting

TherapeuticOrPreventiveProcedure

1,478

1,515

preserve

1531-1551

1540-1551

T86

coronary angioplasty

TherapeuticOrPreventiveProcedure

1,531

1,551

A3

In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.

1395-1607

1,395

1,607

In most patients with diabetes who have multivessel coronary artery disease, @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for improving long-term cardiovascular prognosis.

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1297-1317

1306-1317

T68

estrogen replacement

TherapeuticOrPreventiveProcedure

1,297

1,317

preserve

1364-1372

T70

patients

PatientOrDisabledGroup

1,364

1,372

A4

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal @SUBJECT$ , and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.

Fact

preserve

101-105

T6

with

PROCESS_OF

101

105

preserve

106-114

T4

diabetes

DiseaseOrSyndrome

106

114

preserve

92-100

T3

patients

PatientOrDisabledGroup

92

100

A5

Approximately 80% of all patients with diabetes die of cardiovascular disease.

67-145

67

145

Approximately 80% of all @OBJECT$ @PREDICAT$ @SUBJECT$ die of cardiovascular disease.

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1256-1280

1272-1280

T67

beta-adrenergic blockers

PharmacologicSubstance

1,256

1,280

preserve

1364-1372

T70

patients

PatientOrDisabledGroup

1,364

1,372

A6

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, @SUBJECT$ , postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.

Fact

preserve

1528-1530

T90

to

compared_with

1,528

1,530

preserve

1478-1515

1507-1515

T84

coronary artery bypass grafting

TherapeuticOrPreventiveProcedure

1,478

1,515

preserve

1531-1551

1540-1551

T86

coronary angioplasty

TherapeuticOrPreventiveProcedure

1,531

1,551

A7

In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.

1395-1607

1,395

1,607

In most patients with diabetes who have multivessel coronary artery disease, @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for improving long-term cardiovascular prognosis.

Uncommitted

preserve

1830-1833

T108

for

TREATS

1,830

1,833

preserve

1757-1777

1766-1777

T103

coronary angioplasty

TherapeuticOrPreventiveProcedure

1,757

1,777

preserve

1838-1846

T105

patients

PatientOrDisabledGroup

1,838

1,846

A9

Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.

1750-1898

1,750

1,898

Urgent @SUBJECT$ or thrombolytic therapy should be considered @PREDICAT$ all @OBJECT$ with diabetes who have acute myocardial infarction.

Uncommitted

preserve

1830-1833

T108

for

TREATS

1,830

1,833

preserve

1757-1777

1766-1777

T103

coronary angioplasty

TherapeuticOrPreventiveProcedure

1,757

1,777

preserve

1852-1860

T106

diabetes

DiseaseOrSyndrome

1,852

1,860

A10

Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.

1750-1898

1,750

1,898

Urgent @SUBJECT$ or thrombolytic therapy should be considered @PREDICAT$ all patients with @OBJECT$ who have acute myocardial infarction.

Fact

preserve

1436-1440

T93

have

PROCESS_OF

1,436

1,440

preserve

1441-1476

1469-1476

T83

multivessel coronary artery disease

DiseaseOrSyndrome

1,441

1,476

preserve

1409-1417

T81

patients

PatientOrDisabledGroup

1,409

1,417

A11

In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.

1395-1607

1,395

1,607

In most @OBJECT$ with diabetes who @PREDICAT$ @SUBJECT$ , coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1329-1338

1337-1338

T69

vitamin E

Lipid

1,329

1,338

preserve

1378-1393

1385-1393

T71

type 2 diabetes

DiseaseOrSyndrome

1,378

1,393

A12

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and @SUBJECT$ should be considered @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

386-396

T25

associated

COEXISTS_WITH

386

396

preserve

529-548

539-548

T23

sedentary lifestyle

Finding

529

548

preserve

359-375

T15

hyperinsulinemia

DiseaseOrSyndrome

359

375

A14

Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

325-549

325

549

Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and @SUBJECT$ .

Fact

preserve

386-396

T25

associated

COEXISTS_WITH

386

396

preserve

408-420

T16

hypertension

DiseaseOrSyndrome

408

420

preserve

359-375

T15

hyperinsulinemia

DiseaseOrSyndrome

359

375

A16

Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

325-549

325

549

Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with @SUBJECT$ , atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1297-1317

1306-1317

T68

estrogen replacement

TherapeuticOrPreventiveProcedure

1,297

1,317

preserve

1378-1393

1385-1393

T71

type 2 diabetes

DiseaseOrSyndrome

1,378

1,393

A17

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal @SUBJECT$ , and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

386-396

T25

associated

COEXISTS_WITH

386

396

preserve

434-446

T17

dyslipidemia

DiseaseOrSyndrome

434

446

preserve

359-375

T15

hyperinsulinemia

DiseaseOrSyndrome

359

375

A18

Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

325-549

325

549

Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic @SUBJECT$ , left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

Fact

preserve

1667-1694

1689-1694

T101

left internal mammary graft

PART_OF

1,667

1,694

preserve

1689-1694

T98

graft

Tissue

1,689

1,694

preserve

1667-1688

1681-1688

T97

left internal mammary

BodyPartOrganOrOrganComponent

1,667

1,688

A19

This superiority is mediated in part by the use of a left internal mammary graft to the left anterior descending coronary artery.

1608-1749

1,608

1,749

This superiority is mediated in part by the use of a @OBJECT$ @PREDICAT$ @SUBJECT$ to the left anterior descending coronary artery.

Fact

preserve

386-396

T25

associated

COEXISTS_WITH

386

396

preserve

448-476

465-476

T18

left ventricular hypertrophy

PathologicFunction

448

476

preserve

359-375

T15

hyperinsulinemia

DiseaseOrSyndrome

359

375

A20

Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

325-549

325

549

Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, @SUBJECT$ , impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

Uncommitted

preserve

1830-1833

T108

for

TREATS

1,830

1,833

preserve

1781-1801

1794-1801

T104

thrombolytic therapy

TherapeuticOrPreventiveProcedure

1,781

1,801

preserve

1838-1846

T105

patients

PatientOrDisabledGroup

1,838

1,846

A21

Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.

1750-1898

1,750

1,898

Urgent coronary angioplasty or @SUBJECT$ should be considered @PREDICAT$ all @OBJECT$ with diabetes who have acute myocardial infarction.

Fact

preserve

699-703

T41

with

PROCESS_OF

699

703

preserve

704-712

T36

diabetes

DiseaseOrSyndrome

704

712

preserve

690-698

T35

patients

PatientOrDisabledGroup

690

698

A22

Although all these conditions are associated with atherosclerosis and adverse cardiovascular events, the therapeutic efforts in patients with diabetes have focused predominantly on normalizing glucose levels.

550-776

550

776

Although all these conditions are associated with atherosclerosis and adverse cardiovascular events, the therapeutic efforts in @OBJECT$ @PREDICAT$ @SUBJECT$ have focused predominantly on normalizing glucose levels.

Fact

preserve

1847-1851

T110

with

PROCESS_OF

1,847

1,851

preserve

1852-1860

T106

diabetes

DiseaseOrSyndrome

1,852

1,860

preserve

1838-1846

T105

patients

PatientOrDisabledGroup

1,838

1,846

A23

Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.

1750-1898

1,750

1,898

Urgent coronary angioplasty or thrombolytic therapy should be considered for all @OBJECT$ @PREDICAT$ @SUBJECT$ who have acute myocardial infarction.

Probable

preserve

350-355

T24

leads

CAUSES

350

355

preserve

325-343

333-343

T13

Insulin resistance

PathologicFunction

325

343

preserve

359-375

T15

hyperinsulinemia

DiseaseOrSyndrome

359

375

A24

Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

325-549

325

549

@SUBJECT$ often @PREDICAT$ to @OBJECT$ , which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

Uncommitted

preserve

1830-1833

T108

for

TREATS

1,830

1,833

preserve

1781-1801

1794-1801

T104

thrombolytic therapy

TherapeuticOrPreventiveProcedure

1,781

1,801

preserve

1852-1860

T106

diabetes

DiseaseOrSyndrome

1,852

1,860

A25

Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.

1750-1898

1,750

1,898

Urgent coronary angioplasty or @SUBJECT$ should be considered @PREDICAT$ all patients with @OBJECT$ who have acute myocardial infarction.

Fact

preserve

1418-1422

T92

with

PROCESS_OF

1,418

1,422

preserve

1423-1431

T82

diabetes

DiseaseOrSyndrome

1,423

1,431

preserve

1409-1417

T81

patients

PatientOrDisabledGroup

1,409

1,417

A26

In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.

1395-1607

1,395

1,607

In most @OBJECT$ @PREDICAT$ @SUBJECT$ who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.

Fact

preserve

386-396

T25

associated

COEXISTS_WITH

386

396

preserve

516-523

T22

obesity

DiseaseOrSyndrome

516

523

preserve

359-375

T15

hyperinsulinemia

DiseaseOrSyndrome

359

375

A27

Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.

325-549

325

549

Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral @SUBJECT$ , and sedentary lifestyle.

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1256-1280

1272-1280

T67

beta-adrenergic blockers

PharmacologicSubstance

1,256

1,280

preserve

1378-1393

1385-1393

T71

type 2 diabetes

DiseaseOrSyndrome

1,378

1,393

A28

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, @SUBJECT$ , postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

1373-1377

T76

with

PROCESS_OF

1,373

1,377

preserve

1378-1393

1385-1393

T71

type 2 diabetes

DiseaseOrSyndrome

1,378

1,393

preserve

1364-1372

T70

patients

PatientOrDisabledGroup

1,364

1,372

A29

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for @OBJECT$ @PREDICAT$ @SUBJECT$ .

Uncommitted

preserve

1360-1363

T72

for

TREATS

1,360

1,363

preserve

1208-1254

1244-1254

T66

angiotensin-converting enzyme inhibitors

PharmacologicSubstance

1,208

1,254

preserve

1378-1393

1385-1393

T71

type 2 diabetes

DiseaseOrSyndrome

1,378

1,393

A30

Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.

1138-1394

1,138

1,394

Therapy including aspirin, lipid agents (for example, statins), @SUBJECT$ , beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

1616-1618

T84

in

TREATS

1,616

1,618

preserve

1606-1615

T81

therapies

TherapeuticOrPreventiveProcedure

1,606

1,615

preserve

1633-1646

1639-1646

T83

heart failure

DiseaseOrSyndrome

1,633

1,646

A1

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.

1384-1647

1,384

1,647

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed @SUBJECT$ @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

1616-1618

T84

in

TREATS

1,616

1,618

preserve

1560-1574

1564-1574

T79

ACE inhibitors

PharmacologicSubstance

1,560

1,574

preserve

1633-1646

1639-1646

T83

heart failure

DiseaseOrSyndrome

1,633

1,646

A2

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.

1384-1647

1,384

1,647

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with @SUBJECT$ and all other prescribed therapies @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

1343-1353

T70

inhibition

DISRUPTS

1,343

1,353

preserve

1333-1336

T66

ACE

AminoAcidPeptideOrProtein

1,333

1,336

preserve

1285-1301

T63

vasoconstriction

OrganOrTissueFunction

1,285

1,301

A3

Persistent angiotensin-induced vasoconstriction and endocrine effects, despite ACE inhibition, is one possible explanation.

1248-1383

1,248

1,383

Persistent angiotensin-induced @OBJECT$ and endocrine effects, despite @SUBJECT$ @PREDICAT$ , is one possible explanation.

Fact

preserve

1628-1632

T86

with

PROCESS_OF

1,628

1,632

preserve

1633-1646

1639-1646

T83

heart failure

DiseaseOrSyndrome

1,633

1,646

preserve

1619-1627

T82

patients

PatientOrDisabledGroup

1,619

1,627

A4

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.

1384-1647

1,384

1,647

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in @OBJECT$ @PREDICAT$ @SUBJECT$ .

Fact

preserve

1616-1618

T84

in

TREATS

1,616

1,618

preserve

1560-1574

1564-1574

T79

ACE inhibitors

PharmacologicSubstance

1,560

1,574

preserve

1619-1627

T82

patients

PatientOrDisabledGroup

1,619

1,627

A5

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.

1384-1647

1,384

1,647

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with @SUBJECT$ and all other prescribed therapies @PREDICAT$ @OBJECT$ with heart failure.

Fact

preserve

1188-1246

1188-1197

T58

magnitude of these benefits has been disappointingly small

ISA

1,188

1,246

preserve

1241-1246

T57

small

QuantitativeConcept

1,241

1,246

preserve

1188-1197

T55

magnitude

QuantitativeConcept

1,188

1,197

A6

Angiotensin-converting enzyme (ACE) inhibitors have exerted favorable effects on both quality of life and mortality, but the magnitude of these benefits has been disappointingly small.

1051-1247

1,051

1,247

Angiotensin-converting enzyme (ACE) inhibitors have exerted favorable effects on both quality of life and mortality, but the @OBJECT$ @PREDICAT$ @SUBJECT$ .

Probable

preserve

999-1005

T49

reduce

PREVENTS

999

1,005

preserve

989-994

T46

drugs

PharmacologicSubstance

989

994

preserve

1006-1014

T47

symptoms

SignOrSymptom

1,006

1,014

A7

Certain inotropic drugs may reduce symptoms but shorten life expectancy.

971-1050

971

1,050

Certain inotropic @SUBJECT$ may @PREDICAT$ @OBJECT$ but shorten life expectancy.

Fact

preserve

1616-1618

T84

in

TREATS

1,616

1,618

preserve

1606-1615

T81

therapies

TherapeuticOrPreventiveProcedure

1,606

1,615

preserve

1619-1627

T82

patients

PatientOrDisabledGroup

1,619

1,627

A9

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.

1384-1647

1,384

1,647

The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed @SUBJECT$ @PREDICAT$ @OBJECT$ with heart failure.

Fact

preserve

2214-2223

T133

treatment

TREATS

2,214

2,223

preserve

2196-2209

2200-2209

T128

ACE inhibitor

PharmacologicSubstance

2,196

2,209

preserve

2227-2240

2233-2240

T130

heart failure

DiseaseOrSyndrome

2,227

2,240

A2

High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

1992-2241

1,992

2,241

High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an @SUBJECT$ for @PREDICAT$ of @OBJECT$ .

Fact

preserve

1570-1574

T99

with

PROCESS_OF

1,570

1,574

preserve

1575-1582

T90

anaemia

DiseaseOrSyndrome

1,575

1,582

preserve

1561-1569

T89

patients

PatientOrDisabledGroup

1,561

1,569

A3

L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

1500-1674

1,500

1,674

L-Carnitine supplementation may be appropriate in some @OBJECT$ @PREDICAT$ @SUBJECT$ of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

Fact

preserve

2110-2114

T132

have

PROCESS_OF

2,110

2,114

preserve

2115-2127

T126

hypertension

DiseaseOrSyndrome

2,115

2,127

preserve

2097-2105

T125

patients

PatientOrDisabledGroup

2,097

2,105

A4

High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

1992-2241

1,992

2,241

High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis @OBJECT$ who @PREDICAT$ @SUBJECT$ that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

Fact

preserve

1978-1990

1982-1990

T119

CRF patients

PROCESS_OF

1,978

1,990

preserve

1978-1981

T117

CRF

DiseaseOrSyndrome

1,978

1,981

preserve

1982-1990

T118

patients

PatientOrDisabledGroup

1,982

1,990

A6

Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients.

1847-1991

1,847

1,991

Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in @SUBJECT$ @PREDICAT$ @OBJECT$ .

Fact

preserve

1500-1533

1518-1533

T97

L-Carnitine supplementation

USES

1,500

1,533

preserve

1518-1533

T87

supplementation

TherapeuticOrPreventiveProcedure

1,518

1,533

preserve

1500-1511

T86

L-Carnitine

OrganicChemical

1,500

1,511

A8

L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

1500-1674

1,500

1,674

@OBJECT$ @PREDICAT$ @SUBJECT$ may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

Fact

preserve

355-364

T26

receiving

ADMINISTERED_TO

355

364

preserve

365-372

T24

epoetin

AminoAcidPeptideOrProtein

365

372

preserve

346-354

T23

patients

PatientOrDisabledGroup

346

354

A9

Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin.

184-373

184

373

Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis @OBJECT$ @PREDICAT$ @SUBJECT$ .

Possible

preserve

1975-1977

T120

in

TREATS

1,975

1,977

preserve

1908-1915

T115

epoetin

AminoAcidPeptideOrProtein

1,908

1,915

preserve

1982-1990

T118

patients

PatientOrDisabledGroup

1,982

1,990

A10

Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients.

1847-1991

1,847

1,991

Recent animal studies indicate that the combination of @SUBJECT$ and insulin-like growth factor 1 might be beneficial @PREDICAT$ CRF @OBJECT$ .

Fact

preserve

1017-1032

1025-1032

T66

epoetin therapy

ISA

1,017

1,032

preserve

1017-1024

T61

epoetin

AminoAcidPeptideOrProtein

1,017

1,024

preserve

1025-1032

T62

therapy

TherapeuticOrPreventiveProcedure

1,025

1,032

A11

Vitamin B6 requirements are increased during epoetin therapy, and supplementation at a dose of 100-150 mg/week is recommended.

965-1098

965

1,098

Vitamin B6 requirements are increased during @SUBJECT$ @PREDICAT$ @OBJECT$ , and supplementation at a dose of 100-150 mg/week is recommended.

Possible

preserve

903-910

T57

improve

TREATS

903

910

preserve

844-856

T51

alfacalcidol

PharmacologicSubstance

844

856

preserve

911-918

T53

anaemia

DiseaseOrSyndrome

911

918

A12

The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements.

805-964

805

964

The active vitamin D metabolites @SUBJECT$ and calcitriol may, under some circumstances, @PREDICAT$ @OBJECT$ and reduce epoetin dosage requirements.

Fact

preserve

119-126

T12

treated

TREATS

119

126

preserve

132-139

T8

epoetin

AminoAcidPeptideOrProtein

132

139

preserve

104-112

T7

patients

PatientOrDisabledGroup

104

112

A13

Adjuvant therapy may allow patients being treated with epoetin to derive greater clinical benefits.

77-183

77

183

Adjuvant therapy may allow @OBJECT$ being @PREDICAT$ with @SUBJECT$ to derive greater clinical benefits.

Fact

preserve

2078-2081

T131

for

TREATS

2,078

2,081

preserve

2012-2058

2048-2058

T123

angiotensin-converting enzyme (ACE) inhibitors

PharmacologicSubstance

2,012

2,058

preserve

2115-2127

T126

hypertension

DiseaseOrSyndrome

2,115

2,127

A14

High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

1992-2241

1,992

2,241

High doses of @SUBJECT$ should be reserved @PREDICAT$ dialysis patients who have @OBJECT$ that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

Fact

preserve

2078-2081

T131

for

TREATS

2,078

2,081

preserve

2012-2058

2048-2058

T123

angiotensin-converting enzyme (ACE) inhibitors

PharmacologicSubstance

2,012

2,058

preserve

2097-2105

T125

patients

PatientOrDisabledGroup

2,097

2,105

A15

High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

1992-2241

1,992

2,241

High doses of @SUBJECT$ should be reserved @PREDICAT$ dialysis @OBJECT$ who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.

Probable

preserve

1553-1555

T98

in

TREATS

1,553

1,555

preserve

1518-1533

T87

supplementation

TherapeuticOrPreventiveProcedure

1,518

1,533

preserve

1561-1569

T89

patients

PatientOrDisabledGroup

1,561

1,569

A16

L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

1500-1674

1,500

1,674

L-Carnitine @SUBJECT$ may be appropriate @PREDICAT$ some @OBJECT$ with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

Uncommitted

preserve

37-39

T5

in

TREATS

37

39

preserve

20-36

29-36

T2

adjuvant therapy

TherapeuticOrPreventiveProcedure

20

36

preserve

40-48

T3

patients

PatientOrDisabledGroup

40

48

A17

Is there a role for adjuvant therapy in patients being treated with epoetin?

0-76

0

76

Is there a role for @SUBJECT$ @PREDICAT$ @OBJECT$ being treated with epoetin?

Probable

preserve

1553-1555

T98

in

TREATS

1,553

1,555

preserve

1518-1533

T87

supplementation

TherapeuticOrPreventiveProcedure

1,518

1,533

preserve

1575-1582

T90

anaemia

DiseaseOrSyndrome

1,575

1,582

A18

L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

1500-1674

1,500

1,674

L-Carnitine @SUBJECT$ may be appropriate @PREDICAT$ some patients with @OBJECT$ of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.

Fact

preserve

184-204

189-204

T25

Iron supplementation

USES

184

204

preserve

189-204

T14

supplementation

TherapeuticOrPreventiveProcedure

189

204

preserve

184-188

T13

Iron

BiologicallyActiveSubstance

184

188

A19

Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin.

184-373

184

373

@OBJECT$ @PREDICAT$ @SUBJECT$ is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin.

Fact

preserve

1472-1476

T85

with

PROCESS_OF

1,472

1,476

preserve

1477-1498

T83

hyperhomocysteinaemia

DiseaseOrSyndrome

1,477

1,498

preserve

1463-1471

T82

patients

PatientOrDisabledGroup

1,463

1,471

A20

Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for patients with hyperhomocysteinaemia.

1290-1499

1,290

1,499

Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for @OBJECT$ @PREDICAT$ @SUBJECT$ .

Possible

preserve

903-910

T57

improve

TREATS

903

910

preserve

861-871

T52

calcitriol

Hormone

861

871

preserve

911-918

T53

anaemia

DiseaseOrSyndrome

911

918

A21

The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements.

805-964

805

964

The active vitamin D metabolites alfacalcidol and @SUBJECT$ may, under some circumstances, @PREDICAT$ @OBJECT$ and reduce epoetin dosage requirements.

Possible

preserve

1975-1977

T120

in

TREATS

1,975

1,977

preserve

1908-1915

T115

epoetin

AminoAcidPeptideOrProtein

1,908

1,915

preserve

1978-1981

T117

CRF

DiseaseOrSyndrome

1,978

1,981

A22

Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients.

1847-1991

1,847

1,991

Recent animal studies indicate that the combination of @SUBJECT$ and insulin-like growth factor 1 might be beneficial @PREDICAT$ @OBJECT$ patients.

Fact

preserve

1824-1828

T111

with

PROCESS_OF

1,824

1,828

preserve

1839-1845

T109

kidney

ClinicalAttribute

1,839

1,845

preserve

1800-1803

T106

men

PopulationGroup

1,800

1,803

A23

Androgens potentially could reduce epoetin costs in countries with limited resources, but should only be used in men older than 50 years with a remnant kidney.

1675-1846

1,675

1,846

Androgens potentially could reduce epoetin costs in countries with limited resources, but should only be used in @OBJECT$ older than 50 years @PREDICAT$ a remnant @SUBJECT$ .

Fact

preserve

716-718

T43

in

TREATS

716

718

preserve

687-694

T38

therapy

TherapeuticOrPreventiveProcedure

687

694

preserve

739-749

747-749

T41

Type II DM

DiseaseOrSyndrome

739

749

A2

This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.

636-750

636

750

This 11-year study is comparing conventional @SUBJECT$ to intensive therapy @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

907-916

T63

treatment

TREATS

907

916

preserve

867-874

T54

insulin

AminoAcidPeptideOrProtein

867

874

preserve

921-931

929-931

T58

Type II DM

DiseaseOrSyndrome

921

931

A3

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.

751-1000

751

1,000

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or @SUBJECT$ can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.

Fact

preserve

716-718

T43

in

TREATS

716

718

preserve

708-715

T39

therapy

TherapeuticOrPreventiveProcedure

708

715

preserve

719-727

T40

patients

PatientOrDisabledGroup

719

727

A4

This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.

636-750

636

750

This 11-year study is comparing conventional therapy to intensive @SUBJECT$ @PREDICAT$ @OBJECT$ with Type II DM.

Fact

preserve

907-916

T63

treatment

TREATS

907

916

preserve

843-852

T52

metformin

OrganicChemical

843

852

preserve

921-931

929-931

T58

Type II DM

DiseaseOrSyndrome

921

931

A5

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.

751-1000

751

1,000

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, @SUBJECT$ , acarbose, or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.

Fact

preserve

716-718

T43

in

TREATS

716

718

preserve

708-715

T39

therapy

TherapeuticOrPreventiveProcedure

708

715

preserve

739-749

747-749

T41

Type II DM

DiseaseOrSyndrome

739

749

A6

This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.

636-750

636

750

This 11-year study is comparing conventional therapy to intensive @SUBJECT$ @PREDICAT$ patients with @OBJECT$ .

Fact

preserve

728-732

T45

with

PROCESS_OF

728

732

preserve

739-749

747-749

T41

Type II DM

DiseaseOrSyndrome

739

749

preserve

719-727

T40

patients

PatientOrDisabledGroup

719

727

A7

This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.

636-750

636

750

This 11-year study is comparing conventional therapy to intensive therapy in @OBJECT$ @PREDICAT$ @SUBJECT$ .

Fact

preserve

506-510

T30

with

PROCESS_OF

506

510

preserve

511-521

519-521

T29

Type II DM

DiseaseOrSyndrome

511

521

preserve

497-505

T28

patients

PatientOrDisabledGroup

497

505

A8

Still, the current standard of practice is to attempt to attain glycemic goals in patients with Type II DM.

409-522

409

522

Still, the current standard of practice is to attempt to attain glycemic goals in @OBJECT$ @PREDICAT$ @SUBJECT$ .

Fact

preserve

907-916

T63

treatment

TREATS

907

916

preserve

828-841

T51

sulfonylureas

OrganicChemical

828

841

preserve

921-931

929-931

T58

Type II DM

DiseaseOrSyndrome

921

931

A9

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.

751-1000

751

1,000

The American Diabetes Association's (ADA) guidelines state that either @SUBJECT$ , metformin, acarbose, or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.

Fact

preserve

316-318

T22

in

COEXISTS_WITH

316

318

preserve

268-281

T14

complications

PathologicFunction

268

281

preserve

319-329

327-329

T17

Type II DM

DiseaseOrSyndrome

319

329

A10

Currently, no data exist showing improved outcomes or reduced macrovascular complications with tight glycemic control in Type II DM, and only minimal data shows a reduction of microvascular complications.

186-408

186

408

Currently, no data exist showing improved outcomes or reduced macrovascular @SUBJECT$ with tight glycemic control @PREDICAT$ @OBJECT$ , and only minimal data shows a reduction of microvascular complications.

Fact

preserve

664-673

T42

comparing

compared_with

664

673

preserve

687-694

T38

therapy

TherapeuticOrPreventiveProcedure

687

694

preserve

708-715

T39

therapy

TherapeuticOrPreventiveProcedure

708

715

A11

This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.

636-750

636

750

This 11-year study is @PREDICAT$ conventional @SUBJECT$ to intensive @OBJECT$ in patients with Type II DM.

Fact

preserve

907-916

T63

treatment

TREATS

907

916

preserve

854-862

T53

acarbose

Carbohydrate

854

862

preserve

921-931

929-931

T58

Type II DM

DiseaseOrSyndrome

921

931

A12

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.

751-1000

751

1,000

The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, @SUBJECT$ , or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.

Fact

preserve

716-718

T43

in

TREATS

716

718

preserve

687-694

T38

therapy

TherapeuticOrPreventiveProcedure

687

694

preserve

719-727

T40

patients

PatientOrDisabledGroup

719

727

A13

This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.

636-750

636

750

This 11-year study is comparing conventional @SUBJECT$ to intensive therapy @PREDICAT$ @OBJECT$ with Type II DM.

Fact

preserve

2052-2073

2066-2073

T106

antibacterial therapy

USES

2,052

2,073

preserve

2066-2073

T103

therapy

TherapeuticOrPreventiveProcedure

2,066

2,073

preserve

2052-2065

T102

antibacterial

Antibiotic

2,052

2,065

A2

Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of antibacterial therapy for coronary artery disease.

1926-2102

1,926

2,102

Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of @OBJECT$ @PREDICAT$ @SUBJECT$ for coronary artery disease.

Possible

preserve

357-365

T25

modulate

AFFECTS

357

365

preserve

323-340

331-340

T20

chronic infection

DiseaseOrSyndrome

323

340

preserve

378-387

T21

processes

PhenomenonOrProcess

378

387

A3

With this awareness, the possibility that acute or chronic infection may initiate or modulate these processes in an active area of investigation.

266-423

266

423

With this awareness, the possibility that acute or @SUBJECT$ may initiate or @PREDICAT$ these @OBJECT$ in an active area of investigation.

Fact

preserve

1626-1649

1640-1649

T89

antibacterial treatment

USES

1,626

1,649

preserve

1640-1649

T83

treatment

TherapeuticOrPreventiveProcedure

1,640

1,649

preserve

1626-1639

T82

antibacterial

Antibiotic

1,626

1,639

A4

Finally, recent pilot trials have demonstrated that macrolide antibacterial treatment directed against C. pneumoniae reduces the risk of recurrent coronary events.

1558-1733

1,558

1,733

Finally, recent pilot trials have demonstrated that macrolide @OBJECT$ @PREDICAT$ @SUBJECT$ directed against C. pneumoniae reduces the risk of recurrent coronary events.

Fact

preserve

1330-1353

1346-1353

T71

coronary artery plaques

LOCATION_OF

1,330

1,353

preserve

1330-1345

1339-1345

T69

coronary artery

BodyPartOrganOrOrganComponent

1,330

1,345

preserve

1346-1353

T70

plaques

AcquiredAbnormality

1,346

1,353

A5

In addition, pathological examinations have demonstrated the presence of infectious organisms in coronary artery plaques.

1227-1354

1,227

1,354

In addition, pathological examinations have demonstrated the presence of infectious organisms in @SUBJECT$ @PREDICAT$ @OBJECT$ .

Possible

preserve

50-54

T9

role

AFFECTS

50

54

preserve

58-67

T6

infection

DiseaseOrSyndrome

58

67

preserve

77-90

T7

atherogenesis

PathologicFunction

77

90

A6

A possible role of infection in atherogenesis and acute coronary syndromes.

39-120

39

120

A possible @PREDICAT$ of @SUBJECT$ in @OBJECT$ and acute coronary syndromes.

Uncommitted

preserve

12-15

T3

for

TREATS

12

15

preserve

0-11

T1

Antibiotics

Antibiotic

0

11

preserve

16-37

27-37

T2

myocardial infarction

DiseaseOrSyndrome

16

37

A7

Antibiotics for myocardial infarction?

0-38

0

38

@SUBJECT$ @PREDICAT$ @OBJECT$ ?

Possible

preserve

50-54

T9

role

AFFECTS

50

54

preserve

58-67

T6

infection

DiseaseOrSyndrome

58

67

preserve

95-119

110-119

T8

acute coronary syndromes

DiseaseOrSyndrome

95

119

A8

A possible role of infection in atherogenesis and acute coronary syndromes.

39-120

39

120

A possible @PREDICAT$ of @SUBJECT$ in atherogenesis and @OBJECT$ .

Fact

preserve

2066-2073

T107

therapy

TREATS

2,066

2,073

preserve

2052-2065

T102

antibacterial

Antibiotic

2,052

2,065

preserve

2078-2101

2094-2101

T104

coronary artery disease

DiseaseOrSyndrome

2,078

2,101

A9

Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of antibacterial therapy for coronary artery disease.

1926-2102

1,926

2,102

Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of @SUBJECT$ @PREDICAT$ for @OBJECT$ .

Fact

preserve

561-589

584-589

T39

vascular smooth muscle cells

PART_OF

561

589

preserve

570-589

584-589

T35

smooth muscle cells

Cell

570

589

preserve

561-569

T34

vascular

BodyPartOrganOrOrganComponent

561

569

A10

Infectious organisms may influence the atherosclerotic process through direct local effects on the coronary endothelium, on vascular smooth muscle cells and on macrophages in the atherosclerotic lesion.

424-645

424

645

Infectious organisms may influence the atherosclerotic process through direct local effects on the coronary endothelium, on @OBJECT$ @PREDICAT$ @SUBJECT$ and on macrophages in the atherosclerotic lesion.

Fact

preserve

894-897

T59

had

PROCESS_OF

894

897

preserve

898-909

902-909

T58

hot flashes

SignOrSymptom

898

909

preserve

879-887

T57

patients

PatientOrDisabledGroup

879

887

A1

Fourteen patients (66%) had hot flashes.

870-910

870

910

Fourteen @OBJECT$ (66%) @PREDICAT$ @SUBJECT$ .

Fact

preserve

431-433

T37

in

PROCESS_OF

431

433

preserve

420-430

T30

depression

Finding

420

430

preserve

443-451

T31

patients

PatientOrDisabledGroup

443

451

A2

This pilot study describes the course of menopausal symptoms and the incidence of depression in 21 patients who were likely to become acutely estrogen deficient during treatment for breast cancer.

331-546

331

546

This pilot study describes the course of menopausal symptoms and the incidence of @SUBJECT$ @PREDICAT$ 21 @OBJECT$ who were likely to become acutely estrogen deficient during treatment for breast cancer.

Fact

preserve

716-725

T52

developed

PROCESS_OF

716

725

preserve

726-751

743-751

T47

major depressive disorder

MentalOrBehavioralDysfunction

726

751

preserve

701-709

T46

patients

PatientOrDisabledGroup

701

709

A4

Eight patients (38%) developed major depressive disorder, the majority within 6 months of starting treatment.

695-810

695

810

Eight @OBJECT$ (38%) @PREDICAT$ @SUBJECT$ , the majority within 6 months of starting treatment.

Probable

preserve

236-240

T23

risk

PREDISPOSES

236

240

preserve

158-169

162-169

T15

hot flashes

SignOrSymptom

158

169

preserve

244-275

267-275

T18

major depressive disorder

MentalOrBehavioralDysfunction

244

275

A7

The change of estrogen function, represented by amenorrhea or hot flashes, that results from breast cancer treatment may increase the risk of major depressive disorder in those women undergoing treatment for breast cancer.

96-330

96

330

The change of estrogen function, represented by amenorrhea or @SUBJECT$ , that results from breast cancer treatment may increase the @PREDICAT$ of @OBJECT$ in those women undergoing treatment for breast cancer.

Fact

preserve

63-65

T9

in

PROCESS_OF

63

65

preserve

53-62

T5

syndromes

DiseaseOrSyndrome

53

62

preserve

86-94

T7

patients

PatientOrDisabledGroup

86

94

A8

Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.

0-95

0

95

Iatrogenic acute estrogen deficiency and psychiatric @SUBJECT$ @PREDICAT$ breast cancer @OBJECT$ .

Fact

preserve

833-836

T56

had

PROCESS_OF

833

836

preserve

837-846

T54

dysphoria

MentalOrBehavioralDysfunction

837

846

preserve

818-826

T53

patients

PatientOrDisabledGroup

818

826

A9

Twenty patients (95%) had dysphoria and/or insomnia.

811-869

811

869

Twenty @OBJECT$ (95%) @PREDICAT$ @SUBJECT$ and/or insomnia.

Fact

preserve

66-94

86-94

T8

breast cancer patients

PROCESS_OF

66

94

preserve

66-79

73-79

T6

breast cancer

NeoplasticProcess

66

79

preserve

86-94

T7

patients

PatientOrDisabledGroup

86

94

A10

Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.

0-95

0

95

Iatrogenic acute estrogen deficiency and psychiatric syndromes in @SUBJECT$ @PREDICAT$ @OBJECT$ .

Fact

preserve

972-994

986-994

T68

breast cancer patients

PROCESS_OF

972

994

preserve

972-985

979-985

T62

breast cancer

NeoplasticProcess

972

985

preserve

986-994

T63

patients

PatientOrDisabledGroup

986

994

A11

While this is only pilot data, these data suggest that breast cancer patients whose treatment precipitates menopausal symptoms should be targeted for diagnosis of depression and treated if diagnosed.

911-1128

911

1,128

While this is only pilot data, these data suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ whose treatment precipitates menopausal symptoms should be targeted for diagnosis of depression and treated if diagnosed.

Fact

preserve

63-65

T9

in

PROCESS_OF

63

65

preserve

17-36

26-36

T3

estrogen deficiency

DiseaseOrSyndrome

17

36

preserve

86-94

T7

patients

PatientOrDisabledGroup

86

94

A12

Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.

0-95

0

95

Iatrogenic acute @SUBJECT$ and psychiatric syndromes @PREDICAT$ breast cancer @OBJECT$ .

Probable

preserve

236-240

T23

risk

PREDISPOSES

236

240

preserve

144-154

T14

amenorrhea

DiseaseOrSyndrome

144

154

preserve

244-275

267-275

T18

major depressive disorder

MentalOrBehavioralDysfunction

244

275

A14

The change of estrogen function, represented by amenorrhea or hot flashes, that results from breast cancer treatment may increase the risk of major depressive disorder in those women undergoing treatment for breast cancer.

96-330

96

330

The change of estrogen function, represented by @SUBJECT$ or hot flashes, that results from breast cancer treatment may increase the @PREDICAT$ of @OBJECT$ in those women undergoing treatment for breast cancer.

Fact

preserve

1330-1358

1353-1358

T68

vascular smooth muscle cells

PART_OF

1,330

1,358

preserve

1339-1358

1353-1358

T67

smooth muscle cells

Cell

1,339

1,358

preserve

1330-1338

T66

vascular

BodyPartOrganOrOrganComponent

1,330

1,338

A2

This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells.

1144-1359

1,144

1,359

This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in @OBJECT$ @PREDICAT$ @SUBJECT$ .

Fact

preserve

1327-1329

T69

in

LOCATION_OF

1,327

1,329

preserve

1339-1358

1353-1358

T67

smooth muscle cells

Cell

1,339

1,358

preserve

1305-1312

T65

calcium

BiologicallyActiveSubstance

1,305

1,312

A3

This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells.

1144-1359

1,144

1,359

This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and @OBJECT$ concentration @PREDICAT$ vascular @SUBJECT$ .

Fact

preserve

1832-1841

T97

treatment

TREATS

1,832

1,841

preserve

1727-1749

1745-1749

T91

sodium-restricted diet

TherapeuticOrPreventiveProcedure

1,727

1,749

preserve

1866-1878

T96

hypertension

DiseaseOrSyndrome

1,866

1,878

A4

As to the therapeutic approach, the low-energy sodium-restricted diet associated with increased physical activity, represents the cornerstones of treatment for the obesity-related hypertension.

1674-1879

1,674

1,879

As to the therapeutic approach, the low-energy @SUBJECT$ associated with increased physical activity, represents the cornerstones of @PREDICAT$ for the obesity-related @OBJECT$ .

Fact

preserve

2092-2106

2098-2106

T108

obese patients

PROCESS_OF

2,092

2,106

preserve

2092-2097

T106

obese

DiseaseOrSyndrome

2,092

2,097

preserve

2098-2106

T107

patients

PatientOrDisabledGroup

2,098

2,106

A9

If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive obese patients.

1880-2107

1,880

2,107

If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive @SUBJECT$ @PREDICAT$ @OBJECT$ .

Fact

preserve

129-153

146-153

T13

overweight persons

PROCESS_OF

129

153

preserve

129-139

T6

overweight

SignOrSymptom

129

139

preserve

146-153

T7

persons

PopulationGroup

146

153

A10

While the prevalence of hypertension is clearly increased among the overweight persons, the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood.

61-288

61

288

While the prevalence of hypertension is clearly increased among the @SUBJECT$ @PREDICAT$ @OBJECT$ , the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood.

Fact

preserve

1327-1329

T69

in

LOCATION_OF

1,327

1,329

preserve

1339-1358

1353-1358

T67

smooth muscle cells

Cell

1,339

1,358

preserve

1294-1300

T64

sodium

BiologicallyActiveSubstance

1,294

1,300

A13

This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells.

1144-1359

1,144

1,359

This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased @OBJECT$ and calcium concentration @PREDICAT$ vascular @SUBJECT$ .

Fact

preserve

851-896

887-896

T68

celecoxib, a highly selective COX-2 inhibitor

higher_than

851

896

preserve

851-860

T45

celecoxib

OrganicChemical

851

860

preserve

919-926

T48

placebo

MedicalDevice

919

926

A1

Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.

814-1163

814

1,163

Preliminary data suggest that @SUBJECT$ @PREDICAT$ , is superior to @OBJECT$ and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.

Fact

preserve

1600-1602

T104

as

same_as

1,600

1,602

preserve

1550-1559

T93

rofecoxib

OrganicChemical

1,550

1,559

preserve

1615-1621

T95

NSAIDs

PharmacologicSubstance

1,615

1,621

A2

In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.

1514-1735

1,514

1,735

In the treatment of osteoarthritis, @SUBJECT$ has been shown to be as effective @PREDICAT$ traditional @OBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.

Fact

preserve

997-1009

997-1000

T66

due to

CAUSES

997

1,009

preserve

1010-1024

T54

osteoarthritis

DiseaseOrSyndrome

1,010

1,024

preserve

992-996

T53

pain

SignOrSymptom

992

996

A3

Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.

814-1163

814

1,163

Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ , although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.

Fact

preserve

1600-1602

T103

as

compared_with

1,600

1,602

preserve

1550-1559

T93

rofecoxib

OrganicChemical

1,550

1,559

preserve

1615-1621

T95

NSAIDs

PharmacologicSubstance

1,615

1,621

A4

In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.

1514-1735

1,514

1,735

In the treatment of osteoarthritis, @SUBJECT$ has been shown to be as effective @PREDICAT$ traditional @OBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.

Probable

preserve

771-776

T42

cause

CAUSES

771

776

preserve

629-634

T30

NSAID

PharmacologicSubstance

629

634

preserve

800-812

805-812

T38

side effects

PathologicFunction

800

812

A5

Theoretically, an NSAID that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects.

611-813

611

813

Theoretically, an @SUBJECT$ that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should @PREDICAT$ fewer gastrointestinal @OBJECT$ .

Fact

preserve

1521-1530

T105

treatment

TREATS

1,521

1,530

preserve

1615-1621

T95

NSAIDs

PharmacologicSubstance

1,615

1,621

preserve

1534-1548

T92

osteoarthritis

DiseaseOrSyndrome

1,534

1,548

A6

In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.

1514-1735

1,514

1,735

In the @PREDICAT$ of @OBJECT$ , rofecoxib has been shown to be as effective as traditional @SUBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.

Fact

preserve

1220-1222

T80

as

same_as

1,220

1,222

preserve

1164-1173

T69

Celecoxib

OrganicChemical

1,164

1,173

preserve

1235-1241

T71

NSAIDs

PharmacologicSubstance

1,235

1,241

A8

Celecoxib also has been shown to be as effective as traditional NSAIDs in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers.

1164-1380

1,164

1,380

@SUBJECT$ also has been shown to be as effective @PREDICAT$ traditional @OBJECT$ in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers.

Fact

preserve

851-896

887-896

T64

celecoxib, a highly selective COX-2 inhibitor

ISA

851

896

preserve

851-860

T45

celecoxib

OrganicChemical

851

860

preserve

881-896

887-896

T46

COX-2 inhibitor

OrganicChemical

881

896

A9

Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.

814-1163

814

1,163

Preliminary data suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ , is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.

Datasets:

adlbh
/

factuality-prediction-dataset

Introduction

Dataset Description

Tasks